BioNTech (BNTX) analyst forecast and price target
Analyst forecast
Consensus of 21 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Maintained | Buy | $136.00 from $142.00 | Aug 31, 2026 |
| Evercore ISI Group | Maintained | Outperform | $130.00 from $135.00 | Aug 5, 2026 |
| Citigroup | Maintained | Buy | $125.00 from $130.00 | Aug 5, 2026 |
| Morgan Stanley | Maintained | Overweight | $119.00 from $126.00 | Jul 8, 2026 |
| UBS | Upgraded | Neutral → Buy | $135.00 from $117.00 | May 27, 2026 |
| Bernstein | Initiated Coverage | Market Perform | $96.00 | May 22, 2026 |
| Wells Fargo | Maintained | Overweight | $140.00 from $150.00 | May 6, 2026 |
| Canaccord Genuity | Maintained | Buy | $158.00 from $171.00 | May 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $130.00 | Apr 27, 2026 |
| Morgan Stanley | Maintained | Overweight | $126.00 from $125.00 | Apr 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $130.00 from $140.00 | Mar 31, 2026 |
| BMO Capital | Maintained | Outperform | $128.00 from $143.00 | Mar 11, 2026 |
| Citigroup | Maintained | Buy | $130.00 from $145.00 | Mar 11, 2026 |
| Canaccord Genuity | Maintained | Buy | $171.00 | Mar 11, 2026 |
| Morgan Stanley | Maintained | Overweight | $125.00 from $134.00 | Mar 11, 2026 |
| TD Cowen | Maintained | Hold | $94.00 from $116.00 | Mar 11, 2026 |
| Jefferies | Maintained | Buy | $138.00 from $151.00 | Mar 10, 2026 |
| Goldman Sachs | Upgraded | Neutral → Buy | $142.00 from $115.00 | Jan 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $140.00 from $136.00 | Nov 10, 2025 |
| UBS | Maintained | Neutral | $117.00 from $115.00 | Nov 6, 2025 |
Frequently asked questions
What is the price target for BNTX stock?
The average 12-month analyst price target for BioNTech (BNTX) is $127.50, with a high estimate of $136.00 and a low of $119.00, across 4 analysts.
Is BNTX a buy, sell, or hold?
Analysts covering BioNTech currently average a Buy rating: 15 buy, 5 hold and 1 sell, from 21 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BNTX?
The average price target of $127.50 implies 26.02% upside from the last price of $101.18.
What is the latest analyst rating on BNTX?
On Aug 31, 2026, Canaccord Genuity maintained BioNTech at Buy with a price target of $136.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.